Use of bed side testing of infection in reducing the duration of antibiotic therapy

Use of point-of-care testing for C-reactive protein in reducing the duration of antibiotic therapy in neonatal sepsis- A randomized control trial from a tertiary care NICU in Western India. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069211

Enrollment

Registered

2024-06-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P369- Bacterial sepsis of newborn, unspecified

Interventions

Intervention1: Point of care CRP: In the intervention group, C-reactive protein estimation will be done using a point-of-care machine. (The Lumira CRP test). installed bedside. This is a single-use fl

Eligibility

Inclusion criteria

Inclusion criteria: All neonates with a new episode of clinically suspected sepsis requiring intravenous antibiotics

Exclusion criteria

Exclusion criteria: Life-threatening congenital malformations.

Design outcomes

Primary

Measure	Time frame
duration of antibiotic therapy in neonatal intensive care unit in neonates with sepsis. Timepoint: 4 weeks of life	—

Secondary

Measure	Time frame
To determine the use of point-of-care testing for CRP in reducing the total doses of antibiotics received. To determine the use of point-of-care testing for CRP in reducing the duration of hospital stay. To determine the use of point-of-care testing for CRP in reducing intravenous canula duration. Timepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr Anitha Haribalakrishna

Seth GSMC and KEM Hospital

ani.gem81@gmail.com9769660870

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026